☆ 4.7 Letter

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

LEUKEMIA (2018)

Get Full Text
Add to Collection

Journal

LEUKEMIA
Volume 32, Issue 4, Pages 1034-1037

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.330

Keywords

-

Categories

Oncology Hematology

Funding

  1. Gilead Sciences, Inc. (Foster City, CA, USA)
  2. Incyte
  3. Novartis

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.